An aclacinomycin A-resistant subline of mouse lymphoblastoma L5178Y cells was isolated by successive treatment of tumor-bearing mice with the antibiotic. IC50 (50% growth inhibition) in culture was observed at a drug concentration of 0.22 fig/ml, which was ca. I I times higher than IC50 for the parental cells. The resistant cell line exhibited cross resistance to mitomycin C, actinomycin D, macromomycin, auromomycin, vinblastine, cytochalasin B, and other anthracyclines: daunorubicin, adriamycin, 4'-O-tetrahydropyranyladriamycin, baumycins Al and A2, aclacinomycins B and Y, MA144-S1, 1-deoxypyrromycin, cinerubin A, musettamycin, and pyrromycin. The 1-deoxy group of anthracyclines showed higher degree of cross resistance than the 1-hydroxy group. No significant cross resistance was found with bleomycin A2, neothramycin and blasticidin S. The resistance to aclacinomycin A and cross resistance to adriamycin were also demonstrated by the method of uridine incorporation. The accumulation or retention studies with [3H]adriamycin revealed that the resistance may be due to decreased uptake and increased efflux of the antibiotic in the resistant cells.
table tumors of animals; and exhibits less cardiotoxicity than adriamycin and daunorubicin2). The mechanism of action of aclacinomycin A is similar to that of adriamycin and daunorubicin. Aclacinomycin A produces a preferential inhibition of RNA synthesis over DNA synthesis by intercalating template DNA3,4), and induces strand scission of DNA5). The interaction with tubulin, actin and heavy meromyosin has been also observed4,6).
Human malignant neoplasms sometimes acquire resistance to the anthracycline group of antibiotics, and the mechanism of resistance is not known. For the purpose of studying the mode of anthracycline resistance, we have obtained an adriamycin-resistant subline of mouse lymphoblastoma L5178Y cells in vitro, and examined the mechanism of resistance, which may be attributed to permeability changes7,8).
We have further isolated a resistant subline of L5178Y cells in vivo by administration of aclacinomycin A to mice bearing L5178Y tumor and studied the mechanism of resistance and cross resistance to other antitumor drugs. The results are presented in this publication.
Materials and Methods
[3H] Uridine (40.8 Ci/mmol) was purchased from New England Nuclear, Boston, Mass.
[3H] Adriamycin (28.88 mCi/mmol; 49.8 p.Ci/mg), a product of Farmitalia, was kindly given by Kyowa Hakko Co., Tokyo. The radiochemical purity was higher than 98 % by TLC. Aclacinomycin A and related anthracyclines were generously supplied by Dr. T. OKI, Central Research Lab., Sanraku-Ocean Co., Fujisawa, Kanagawa. Adriamycin and mitomycin C (Kyowa Hakko Co.), bleomycin A2 (Nippon Kayaku Co.), neothramycin and daunorubicin (Meiji Seika Kaisha, Ltd.), blasticidin S (Kaken Chemical Co. ), vinblastine (Eli Lilly & Co.) and cytochalasin B (Adrich Chemical Co.) were also used. Other chemicals were of the highest grade commercially available. [3H] adriamycin into the sensitive and resistant sublines is presented in Fig. 4 . The accumulation of the antibiotic was observed to be higher in the parental cells than in the resistant cells with washing the cells in buffered saline by centrifugation (Fig. 4B) ; but no significant difference was found between both cell lines in the absence of washing (Fig. 4A) . somewhat more tightly than the latter (Fig. 5) .
Since the accumulation of adriamycin in the cells could be due to differential rates of uptake and release by the cells and to affinities for the chemoreceptors (DNA, tubulin etc.), the efflux of the drug from the cells was examined with the sensitive and resistant cell lines (Fig. 6) . The resistant cells exhibited a higher tendency to release the antibiotic than the sensitive cells. 
